Debra Zack
Equibles does not estimate personal net worth.
About Debra Zack
Exagen Inc. reported in an 8-K filed December 5, 2022 that Debra Zack was terminated as Chief Medical Officer, effective December 5, 2022. The proxy statement of Exagen Inc. reports total compensation of $1,025,956 for Debra Zack in fiscal 2022, including a base salary of $373,685. Disclosed compensation is on record for 3 fiscal years.
“On December 5, 2022, Debra Zack, M.D., Ph.D., the Company's Chief Medical Officer, was removed from her position and her employment terminated in connection with the Reduction in Force.”
Affiliation history
-
Exagen Inc. (XGN)
Proxy statement
Start not stated–2022-12-05
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Exagen Inc. (XGN) | M.D., Ph.D. former Chief Medical Officer | $373,685 | $1,025,956 |
| 2021 | Exagen Inc. (XGN) | M.D., Ph.D. former Chief Medical Officer | $415,523 | $1,430,559 |
| 2020 | Exagen Inc. (XGN) | M.D., Ph.D. Chief Medical Officer Amounts for 2021 represent the full grant date fair value of restricted stock unit awards granted to the named executive officer in the applicable year, as computed in accordance with ASC Topic 718, Compensation-Stock Compensation, rather than the amounts paid to or realized by the named executive officer. For a discussion of valuation assumptions used in the calculations, see Note 2 and Note 8 to our audited financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 22, 2022. Amounts for 2021 reflect the aggregate grant date fair value of stock options granted in 2021. Each option grant has been computed in accordance with ASC Topic 718, Compensation-Stock Compensation. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. The assumptions that we used to calculate these amounts are discussed in Note 2 and Note 8 to our audited financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 22, 2022. Amounts for 2021 represent the non-discretionary portion of cash bonuses paid in January 2022 with respect to 2021 corporate performance under the bonus plan. For additional information, see -"Bonus", below. Represents employer matching contributions under our 401(k) plan on behalf of each named executive officer. | $296,692 | $1,122,282 |